Wednesday, December 6, 2023
(ISSN: 1743-4254, 1743-4262)
Nature Clinical Practice Oncology
provides oncologists with authoritative and timely interpretations of key developments in the field, translating the latest findings into clinical practice.
Content includes editorial and opinion pieces, highlights from the current literature, commentaries on the application of recent research to practical patient care, comprehensive reviews, and in-depth case studies. Content is subject to rigorous peer-review.
Coverage includes pathology, diagnosis, treatment (e.g. chemotherapy, radiotherapy, surgery), prevention, and palliative care of all types of human malignant disease. An international Advisory Board ensures comprehensive coverage throughout the year, with discussion of topical issues included as soon as possible after publication of the original research.
All content is editorially independent. Authors are asked to state any professional or financial situations that may be perceived as causing a conflict of interest with respect to integrity of content.
Contact information is available at: http://www.nature.com/ncponc/about_journal/contact_the_journal.html.
Subscription information is available at:
http://www.nature.com/clinicalpractice/subscription_info/index.html.
Reprint information is available at:
http://www.naturereprints.com/.
Nature Publishing Group is a division of Macmillan Publishers Limited, of Brunel Road, Houndmills, Basingstoke, Hampshire, RG21 6XS. Registered Number 785998 England.
Click here for information about the Editor-in-Chief.
Click here for information on the Advisory Board.
Nature Clinical Practice journals will be submitted to the following services for inclusion in their products: PubMed/Medline, EMBASE, Cambridge Scientific Abstracts, INIST, Chemical Abstracts Service, The H. W. Wilson Company, Thomson Scientific, and others as appropriate.
For information about Author Guidelines click here.
